Evidence map›Paper›PMID 36039910›Full record

ArticleFuture oncology (London, England)2022

A phase II study of TAS-117 in patients with advanced solid tumors harboring germline

Jordi Rodón, Pauline Funchain, Theodore W Laetsch, Hendrik-Tobias Arkenau, Alice Hervieu, Christian F Singer, Yonina R Murciano-Goroff, Sant P Chawla, Kristin Anthony, Ikuo Yamamiya and 5 more

Open access · hybridAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 4 countries.

Jordi RodónDepartment of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-6467-3632
Pauline FunchainCleveland Clinic, Cleveland, OH 44195, USA.ORCID 0000-0002-7568-8626
Theodore W LaetschChildren's Hospital of Philadelphia, & University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-8497-3138
Hendrik-Tobias ArkenauSarah Cannon Research Institute, London, UK, & Cancer Institute, University College London, London, W1G 6AD, UK.ORCID 0000-0002-2015-1549
Alice HervieuCentre Georges-François Leclerc, Dijon, France.
Christian F SingerDept of OB/GYN & Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.ORCID 0000-0003-1294-0027
Yonina R Murciano-GoroffMemorial Sloan Kettering Cancer Center, New York City, NY 10065, USA.ORCID 0000-0001-9027-2891
Sant P ChawlaSarcoma Oncology Research Center, Santa Monica, CA 90403, USA.
Kristin AnthonyThe PTEN Hamartoma Tumor Syndrome Foundation, Huntsville, AL 35806, USA.ORCID 0000-0003-3268-346X
Ikuo YamamiyaTaiho Oncology, Princeton, NJ 08540, USA.
Mei LiuTaiho Oncology, Princeton, NJ 08540, USA.
Abdel-Baset HalimTaiho Oncology, Princeton, NJ 08540, USA.
Karim A BenhadjiTaiho Oncology, Princeton, NJ 08540, USA.ORCID 0000-0001-9883-6970
Osamu TakahashiTaiho Oncology, Princeton, NJ 08540, USA.
Suzette DelalogeInstitut Gustave Roussy, Villejuif, 94805, France.ORCID 0000-0003-2106-9165
Taiho Oncology (United States) · USCentre Georges François Leclerc · FRChildren's Hospital of Philadelphia · USCleveland Clinic · USComprehensive Cancer Center Vienna · ATInstitut Gustave Roussy · FRMemorial Sloan Kettering Cancer Center · USPTEN Hamartoma Tumor Syndrome Foundation · USSarah Cannon Research Institute · GBSarcoma Oncology Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Clinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0M
NCATS NIH HHS UL1 TR000457NCATS NIH HHS UL1 TR001873NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PTEN acts as a potent tumor suppressor within the PI3K/AKT/mTOR pathway. Germline mutations in the

Indexed as

Hamartoma Syndrome, MultipleNeoplasmsClinical Trials, Phase II as TopicGerm CellsGerm-Line MutationHeterocyclic Compounds, 3-RingHumansPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktPTEN Phosphohydrolase3-amino-1-methyl-3-(4-(3-phenyl-5H- imidazo(1,2-c)pyrido(3,4-e)(1,3)oxazin-2-yl)phenyl)cyclobutanolHeterocyclic Compounds, 3-RingPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePTEN protein, humanadvanced solid tumorclinical trialCowden syndromegermline PTEN mutationPTEN hamartoma tumor syndromePTEN inactivationTAS-117

Identifiers

PMID36039910
PMCPMC10334253
OpenAlexW4293577376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.